No abstract available
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Capecitabine
-
Clinical Trials, Phase III as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Drug Delivery Systems*
-
Drug Resistance, Neoplasm
-
ErbB Receptors / antagonists & inhibitors
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Forecasting
-
Humans
-
Lapatinib
-
Neoplasm Proteins / antagonists & inhibitors*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / administration & dosage
-
Randomized Controlled Trials as Topic
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Quinazolines
-
Lapatinib
-
Deoxycytidine
-
Capecitabine
-
EGFR protein, human
-
ErbB Receptors
-
Receptor, ErbB-2
-
Trastuzumab
-
Fluorouracil